Volume | 170,471 |
|
|||||
News | - | ||||||
Day High | 18.45 | Low High |
|||||
Day Low | 16.6201 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
NewAmsterdam Pharma Company NV | NAMS | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
17.77 | 16.6201 | 18.45 | 17.11 | 17.84 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
2,370 | 170,471 | US$ 17.19 | US$ 2,931,194 | - | 5.6326 - 26.35 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
15:01:56 | priorref | 287 | US$ 17.11 | USD |
NewAmsterdam Pharma Company NV Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
1.53B | 89.27M | - | 14.09M | -176.94M | -1.98 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
NewAmsterdam Pharma Comp... News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical NAMS Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 19.87 | 20.4986 | 16.6201 | 19.57 | 185,451 | -2.76 | -13.89% |
1 Month | 19.59 | 20.4986 | 16.6201 | 19.24 | 147,848 | -2.48 | -12.66% |
3 Months | 22.82 | 24.79 | 16.6201 | 20.28 | 173,228 | -5.71 | -25.02% |
6 Months | 11.00 | 26.35 | 10.1201 | 20.06 | 196,753 | 6.11 | 55.55% |
1 Year | 12.61 | 26.35 | 5.6326 | 16.39 | 153,009 | 4.50 | 35.69% |
3 Years | 11.00 | 32.88 | 5.6326 | 15.72 | 116,968 | 6.11 | 55.55% |
5 Years | 11.00 | 32.88 | 5.6326 | 15.72 | 116,968 | 6.11 | 55.55% |
NewAmsterdam Pharma Comp... Description
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, develops oral and non-statin medicines for patients at high risk of cardiovascular disease. Its lead product candidate is obicetrapib, a next generation, oral, and low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in four ongoing Phase 3 and Phase 2b clinical trials as both a monotherapy and a combination therapy with ezetimibe for lowering LDL-C and preventing major adverse cardiovascular events (MACE). NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands. |